Ali Rizvi to Animals
This is a "connection" page, showing publications Ali Rizvi has written about Animals.
Connection Strength
0.238
-
Metabolic Syndrome: From Molecular Mechanisms to Novel Therapies. Int J Mol Sci. 2021 Sep 17; 22(18).
Score: 0.058
-
Incretin-based therapies, glucometabolic health and endovascular inflammation. Curr Pharm Des. 2014; 20(31):4953-60.
Score: 0.034
-
Adipokines and lipoproteins: modulation by antihyperglycemic and hypolipidemic agents. Metab Syndr Relat Disord. 2014 Feb; 12(1):1-10.
Score: 0.034
-
Inclisiran: a small interfering RNA strategy targeting PCSK9 to treat hypercholesterolemia. Expert Opin Drug Saf. 2022 Jan; 21(1):9-20.
Score: 0.015
-
The role of GLP-1 receptor agonists during COVID-19 pandemia: a hypothetical molecular mechanism. Expert Opin Drug Saf. 2021 Nov; 20(11):1309-1315.
Score: 0.014
-
The Evolving Role of Fetuin-A in Nonalcoholic Fatty Liver Disease: An Overview from Liver to the Heart. Int J Mol Sci. 2021 Jun 21; 22(12).
Score: 0.014
-
Novel Therapeutical Approaches to Managing Atherosclerotic Risk. Int J Mol Sci. 2021 Apr 28; 22(9).
Score: 0.014
-
Cardiovascular outcomes trials with incretin-based medications: a critical review of data available on GLP-1 receptor agonists and DPP-4 inhibitors. Metabolism. 2020 10; 111:154343.
Score: 0.013
-
Incretins, Pregnancy, and Gestational Diabetes. Curr Pharm Biotechnol. 2016; 17(7):597-602.
Score: 0.010
-
Uric acid metabolism in pre-hypertension and the metabolic syndrome. Curr Vasc Pharmacol. 2014; 12(4):572-85.
Score: 0.009
-
A review of the cardiovascular and anti-atherogenic effects of ghrelin. Curr Pharm Des. 2013; 19(27):4953-63.
Score: 0.008
-
Combined dyslipidemia: should the focus be LDL cholesterol or atherogenic dyslipidemia? Curr Pharm Des. 2013; 19(21):3858-68.
Score: 0.008
-
Glucose lowering and anti-atherogenic effects of incretin-based therapies: GLP-1 analogues and DPP-4-inhibitors. Expert Opin Investig Drugs. 2009 Oct; 18(10):1495-503.
Score: 0.006